BACKGROUND: As rituximab combined with CHOP improves complete remission and overall survival in diffuse large B-cell lymphoma, intensified chemotherapy followed by autologous stem-cell transplantation has also been advocated for high-risk patients. The aim of this study was to establish whether or not combining rituximab with high-dose chemotherapy and auto-transplantation also benefits patient survival. DESIGN AND METHODS: The LNH2003-3 study was a phase II trial including diffuse large B-cell lymphoma patients with 2 or 3 International Prognostic Index factors. They received four cycles of intensive biweekly chemotherapy with rituximab, doxorubicine, cyclophosphamide, vindesine, bleomycine, prednisolone (R-ACVBP) followed by auto-transplantation in responding patients. Two hundred and nine patients under 60 years of age were included in the study and 155 responding patients underwent auto-transplantation. In addition, a case-control study was performed by matching (1:1) 181 patients treated with R-ACVBP with ACVBP patients not given rituximab but submitted to auto-transplantation from the previous LNH1998-3 trial. RESULTS: With a median follow up of 45 months, 4-year progression-free survival and overall survival were estimated at 76% (CI: 69-81) and 78% (CI: 72-83), respectively. There was no difference between patients with 2 or 3 International Prognostic Index factors. Four year progression-free survival was significantly higher in R-ACVBP than ACVBP patients (74% vs. 58%; P=0.0005). There was also a significant increase in 4-year overall survival (76% vs. 68%; P=0.0494). CONCLUSIONS: In high-risk diffuse large B-cell lymphoma patients, treatment with R-ACVBP followed by auto-transplantation results in a 78% 4-year overall survival which should be compared to other approaches.
BACKGROUND: As rituximab combined with CHOP improves complete remission and overall survival in diffuse large B-cell lymphoma, intensified chemotherapy followed by autologous stem-cell transplantation has also been advocated for high-risk patients. The aim of this study was to establish whether or not combining rituximab with high-dose chemotherapy and auto-transplantation also benefits patient survival. DESIGN AND METHODS: The LNH2003-3 study was a phase II trial including diffuse large B-cell lymphomapatients with 2 or 3 International Prognostic Index factors. They received four cycles of intensive biweekly chemotherapy with rituximab, doxorubicine, cyclophosphamide, vindesine, bleomycine, prednisolone (R-ACVBP) followed by auto-transplantation in responding patients. Two hundred and nine patients under 60 years of age were included in the study and 155 responding patients underwent auto-transplantation. In addition, a case-control study was performed by matching (1:1) 181 patients treated with R-ACVBP with ACVBP patients not given rituximab but submitted to auto-transplantation from the previous LNH1998-3 trial. RESULTS: With a median follow up of 45 months, 4-year progression-free survival and overall survival were estimated at 76% (CI: 69-81) and 78% (CI: 72-83), respectively. There was no difference between patients with 2 or 3 International Prognostic Index factors. Four year progression-free survival was significantly higher in R-ACVBP than ACVBP patients (74% vs. 58%; P=0.0005). There was also a significant increase in 4-year overall survival (76% vs. 68%; P=0.0494). CONCLUSIONS: In high-risk diffuse large B-cell lymphomapatients, treatment with R-ACVBP followed by auto-transplantation results in a 78% 4-year overall survival which should be compared to other approaches.
Authors: C Haioun; N Mounier; J F Emile; D Ranta; B Coiffier; H Tilly; C Récher; C Fermé; J Gabarre; R Herbrecht; F Morchhauser; C Gisselbrecht Journal: Ann Oncol Date: 2009-06-30 Impact factor: 32.976
Authors: Kieron Dunleavy; Stefania Pittaluga; Myron S Czuczman; Sandeep S Dave; George Wright; Nicole Grant; Margaret Shovlin; Elaine S Jaffe; John E Janik; Louis M Staudt; Wyndham H Wilson Journal: Blood Date: 2009-04-20 Impact factor: 22.113
Authors: C Tarella; M Zanni; M Di Nicola; C Patti; R Calvi; A Pescarollo; V Zoli; A Fornari; D Novero; A Cabras; M Stella; A Comino; D Remotti; M Ponzoni; D Caracciolo; M Ladetto; M Magni; L Devizzi; R Rosato; M Boccadoro; M Bregni; P Corradini; A Gallamini; I Majolino; S Mirto; A M Gianni Journal: Leukemia Date: 2007-06-07 Impact factor: 11.528
Authors: Wyndham H Wilson; Kieron Dunleavy; Stefania Pittaluga; Upendra Hegde; Nicole Grant; Seth M Steinberg; Mark Raffeld; Martin Gutierrez; Bruce A Chabner; Louis Staudt; Elaine S Jaffe; John E Janik Journal: J Clin Oncol Date: 2008-03-31 Impact factor: 44.544
Authors: Reyes Arranz; Eulogio Conde; Carlos Grande; Maria Victoria Mateos; Marco Gandarillas; Carmen Albo; Juan J Lahuerta; José M Fernández-Rañada; Miguel T Hernández; Natalia Alonso; José A García Vela; Sebastián Garzón; José Rodríguez; Dolores Caballero Journal: Eur J Haematol Date: 2007-12-18 Impact factor: 2.997
Authors: Patrick J Stiff; Joseph M Unger; James R Cook; Louis S Constine; Stephen Couban; Douglas A Stewart; Thomas C Shea; Pierluigi Porcu; Jane N Winter; Brad S Kahl; Thomas P Miller; Raymond R Tubbs; Deborah Marcellus; Jonathan W Friedberg; Kevin P Barton; Glenn M Mills; Michael LeBlanc; Lisa M Rimsza; Stephen J Forman; Richard I Fisher Journal: N Engl J Med Date: 2013-10-31 Impact factor: 91.245
Authors: Yasuhiro Oki; Jason R Westin; Francisco Vega; Hubert Chuang; Nathan Fowler; Sattva Neelapu; Fredrick B Hagemeister; Peter McLaughlin; Larry W Kwak; Jorge E Romaguera; Michelle Fanale; Anas Younes; Maria Alma Rodriguez; Robert Z Orlowski; Michael Wang; Souzanne T Ouzounian; Felipe Samaniego; Luis Fayad Journal: Br J Haematol Date: 2013-10-01 Impact factor: 6.998
Authors: Hervé Ghesquieres; Susan L Slager; Fabrice Jardin; Amelie S Veron; Yan W Asmann; Matthew J Maurer; Thierry Fest; Thomas M Habermann; Marie C Bene; Anne J Novak; Sylvain Mareschal; Corinne Haioun; Thierry Lamy; Stephen M Ansell; Herve Tilly; Thomas E Witzig; George J Weiner; Andrew L Feldman; Ahmet Dogan; Julie M Cunningham; Curtis L Olswold; Thierry Jo Molina; Brian K Link; Noel Milpied; David G Cox; Gilles A Salles; James R Cerhan Journal: J Clin Oncol Date: 2015-10-12 Impact factor: 44.544
Authors: Matthew J Maurer; Hervé Ghesquières; Brian K Link; Jean-Philippe Jais; Thomas M Habermann; Carrie A Thompson; Corinne Haioun; Cristine Allmer; Patrick B Johnston; Richard Delarue; Ivana N Micallef; Frederic Peyrade; David J Inwards; Nicolas Ketterer; Umar Farooq; Olivier Fitoussi; William R Macon; Thierry J Molina; Sergei Syrbu; Andrew L Feldman; Susan L Slager; George J Weiner; Stephen M Ansell; James R Cerhan; Gilles A Salles; Thomas E Witzig; Hervé Tilly; Grzegorz S Nowakowski Journal: J Clin Oncol Date: 2018-04-19 Impact factor: 44.544
Authors: Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544
Authors: Lawrence G Lum; Archana Thakur; Qin Liu; Abhinav Deol; Zaid Al-Kadhimi; Lois Ayash; Muneer H Abidi; Cassara Pray; Elyse N Tomaszewski; Patricia A Steele; Dana L Schalk; Hiroshi Yano; Alice Mitchell; Melissa Dufresne; Joseph P Uberti; Voravit Ratanatharathorn Journal: Biol Blood Marrow Transplant Date: 2013-03-22 Impact factor: 5.742
Authors: D Rossille; M Gressier; D Damotte; D Maucort-Boulch; C Pangault; G Semana; S Le Gouill; C Haioun; K Tarte; T Lamy; N Milpied; T Fest Journal: Leukemia Date: 2014-04-15 Impact factor: 11.528
Authors: Hervé Ghesquières; Beth R Larrabee; Corinne Haioun; Brian K Link; Aurélie Verney; Susan L Slager; Nicolas Ketterer; Stephen M Ansell; Richard Delarue; Matthew J Maurer; Olivier Fitoussi; Thomas M Habermann; Fréderic Peyrade; Ahmet Dogan; Thierry J Molina; Anne J Novak; Hervé Tilly; James R Cerhan; Gilles Salles Journal: Hematol Oncol Date: 2016-06-10 Impact factor: 5.271